Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
POTENTIAL: Preoperative nivolumab in stage I non-small cell lung cancer
jRCT2061180016Phase 2Active, not recruiting
- Sponsor
- Ono Pharmaceutical
- Start
- Apr 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nivolumab in non-small cell lung cancer (NSCLC), sponsored by Ono Pharmaceutical. Primary endpoint: Pathological complete response rate. Started Apr 2019; status: active, not recruiting.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT2061180016.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2061180016.